GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Willow Biosciences Inc (FRA:3D7) » Definitions » EV-to-EBITDA

Willow Biosciences (FRA:3D7) EV-to-EBITDA : -0.93 (As of Apr. 28, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Willow Biosciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Willow Biosciences's enterprise value is €7.11 Mil. Willow Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.63 Mil. Therefore, Willow Biosciences's EV-to-EBITDA for today is -0.93.

The historical rank and industry rank for Willow Biosciences's EV-to-EBITDA or its related term are showing as below:

FRA:3D7' s EV-to-EBITDA Range Over the Past 10 Years
Min: -208.05   Med: -0.92   Max: 4.85
Current: -0.94

During the past 13 years, the highest EV-to-EBITDA of Willow Biosciences was 4.85. The lowest was -208.05. And the median was -0.92.

FRA:3D7's EV-to-EBITDA is ranked worse than
100% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.19 vs FRA:3D7: -0.94

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-28), Willow Biosciences's stock price is €0.0575. Willow Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.069. Therefore, Willow Biosciences's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Willow Biosciences EV-to-EBITDA Historical Data

The historical data trend for Willow Biosciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Willow Biosciences EV-to-EBITDA Chart

Willow Biosciences Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.73 -3.19 -9.00 0.01 -1.03

Willow Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 -0.09 -0.81 -0.85 -1.03

Competitive Comparison of Willow Biosciences's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Willow Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Willow Biosciences's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Willow Biosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Willow Biosciences's EV-to-EBITDA falls into.



Willow Biosciences EV-to-EBITDA Calculation

Willow Biosciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=7.109/-7.63
=-0.93

Willow Biosciences's current Enterprise Value is €7.11 Mil.
Willow Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Willow Biosciences  (FRA:3D7) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Willow Biosciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0575/-0.069
=At Loss

Willow Biosciences's share price for today is €0.0575.
Willow Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.069.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Willow Biosciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Willow Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Willow Biosciences (FRA:3D7) Business Description

Traded in Other Exchanges
Address
202, 1201 5th Street SW, Calgary, AB, CAN, T2R 0Y6
Willow Biosciences Inc is a Canadian biotechnology company. It has only one reportable segment engaged in developing and producing high-purity, plant-derived ingredients for consumer care, food and beverage, and pharmaceutical products. Geographically, it derives a majority of its revenue from Canada.

Willow Biosciences (FRA:3D7) Headlines

No Headlines